ACE-86225106

N/A

Report date: 2026/04/17 20:02:02
NME

Base Information

Drug NameACE-86225106
Drug Alias NameACE-86225106ACE86225106ACE-106
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionPoly (ADP-Ribose) polymerase 1 inhibitors
TargetsPoly (ADP-Ribose) polymerase 1
Therapy Area/IndicationsSolid tumoursProstatic NeoplasmsOvarian Neoplasms +[4] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryMainland China
CombinationsNo
Global Highest StatusPhase 2 Clinical
Highest Status in ChinaPhase 2 Clinical
Originator CompaniesAcerand Therapeutics (Shanghai) Ltd
China Registration ClassClass 1 Chemical Drug in China

Develop Information

Active CompaniesAcerand Therapeutics (Shanghai) Ltd
Inactive CompaniesN/A
Active IndicationsSolid tumoursProstatic NeoplasmsOvarian Neoplasms +[4] 
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A